drugset / Trial / NCT03283761
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Phase 2
Completed
39 enrolled
Al B. Benson, III, MD
Big Ten Cancer Research Consortium · collabCelgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single-arm phase II, multi-institutional trial to evaluate the efficacy and safety of the combination of nab-paclitaxel and FOLFOX (FOLFOX-A) as first line therapy for patients diagnosed with histologically-confirmed advanced gastric/GEJ adenocarcinoma.
Timeline
- Start
- 2017-09-21
- Primary completion
- 2022-12-27
- Completion
- 2023-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 1200 mg/m2 | Intravenous |